NeuroMetrix Inc represents values of innovation, quality, and patient-centered care in the field of neurology and medical technology. The company is committed to developing advanced solutions that improve the lives of patients suffering from chronic conditions, particularly those related to nerve disorders. With a customer-centric approach, NeuroMetrix Inc aims to provide cutting-edge diagnostic and therapeutic products that enable healthcare professionals to deliver more accurate diagnoses and personalized treatments. By combining medical expertise with technological advancements, NeuroMetrix Inc is dedicated to enhancing the well-being and outcomes of individuals battling neurological conditions.

NeuroMetrix Inc is primarily present in the United States, focusing on the domestic market.

NeuroMetrix Inc, a renowned company in the medical device industry, has achieved several significant milestones throughout its history. The company developed and launched the innovative wearable technology device, Quell, which is designed to provide non-invasive pain relief and enhance the quality of life for individuals suffering from chronic pain. NeuroMetrix Inc also obtained FDA clearance for numerous products, including SENSUS, a wearable pain therapy device. Furthermore, the company has forged strategic partnerships, expanding its market reach and enhancing its product portfolio. With its dedication to innovation and commitment to improving pain management, NeuroMetrix Inc continues to lead the way in the medical device industry and bring relief to countless individuals worldwide.

NeuroMetrix Inc. is a renowned medical technology company with a notable background and history. Established in 1996, the company focuses on developing innovative solutions for the diagnosis and monitoring of chronic neurological diseases and disorders. With a strong emphasis on research and development, NeuroMetrix has pioneered breakthroughs in the field of neurodiagnostics, particularly in the areas of neuropathy and neurodegenerative conditions. The company's flagship product, Quell, is a wearable therapeutic device that utilizes neurostimulation technology to provide relief from chronic pain. Over the years, NeuroMetrix Inc. has consistently demonstrated its commitment to improving patients' lives through groundbreaking advancements in neurological healthcare.

The main competitors of NeuroMetrix Inc in the market are companies like Medtronic plc, Abbott Laboratories, and Becton, Dickinson and Company.

NeuroMetrix Inc is primarily active in the medical technology industry.

The business model of NeuroMetrix Inc revolves around developing and commercializing innovative medical devices for the diagnosis and treatment of neurological disorders. NeuroMetrix primarily focuses on the development of wearable neurostimulation devices to address chronic pain management and peripheral neuropathy. The company's flagship product is Quell, a wearable pain relief device that utilizes neurostimulation technology. By leveraging advanced sensor and digital health technologies, NeuroMetrix aims to improve patient outcomes and quality of life. With a strong emphasis on researching and developing non-invasive solutions, NeuroMetrix aims to provide effective and accessible solutions for neurological disorders.

NeuroMetrix KGV yra 0,08.

NeuroMetrix KUV yra 0,08.

AlleAktien kokybės įvertis NeuroMetrix yra 3/10.

tikėtina NeuroMetrix pardavimai yra 39,23 mln. USD.

tikėtina NeuroMetrix pelnas yra 36,18 mln. USD.

NeuroMetrix Inc is an American company specialized in the development and marketing of medical devices for the diagnosis and treatment of neurological disorders. The company was founded in 1996 and is headquartered in Woburn, Massachusetts. NeuroMetrix's business model is focused on developing and establishing innovative medical products in the market. The company is divided into three main divisions: diagnostics, therapy, and wellness. The diagnostics division of NeuroMetrix includes products such as the NC-stat System, a portable device that performs peripheral nervous system diagnostics. The system is used by doctors and healthcare providers to detect and monitor diseases such as diabetic neuropathy. The therapy division of NeuroMetrix focuses on the treatment of pain and other neurological disorders. The company offers products such as the SENSUS Pain Therapy Device, which is used to relieve chronic pain. The SENSUS device stimulates the peripheral nerves at low frequencies to reduce pain in the back, leg, ankle, foot, and knee areas. The wellness division of NeuroMetrix includes products such as the Quell System, a wearable device worn on the ankle that helps reduce pain and insomnia. The Quell System uses a neurological method to stimulate the body's natural pain relief mechanisms. NeuroMetrix has introduced its products in the US and internationally. The company works closely with healthcare providers and insurance companies to ensure that its products are covered by insurance and can be used in practice. Another important aspect of NeuroMetrix's business model is continuous research and development. The company constantly invests in new technologies and products to strengthen its position in the medical device industry. Additionally, the company collaborates closely with clinicians and scientists to identify and develop new medical applications for its products. In addition to its innovative product range, NeuroMetrix places great emphasis on high product quality and customer satisfaction. The company works closely with customers to ensure that its products meet their needs and requirements. Furthermore, NeuroMetrix provides excellent customer support and training for medical personnel to ensure the effective and safe use of its products. In summary, NeuroMetrix Inc's business model is based on the successful marketing of medical diagnosis and treatment devices through innovative technologies and close collaboration with customers and clinicians. The company focuses on constant product development and works closely with insurance companies and healthcare providers to ensure that its products are used by doctors and patients in practice.

NeuroMetrix moka dividendą 0 USD, kuris yra paskirstytas per išmokas per metus.

Dividenda šiuo metu negali būti apskaičiuota NeuroMetrix arba įmonė dividendų nemoka.

NeuroMetrix ISIN yra US6412558073.

NeuroMetrix WKN yra A2PVRC.

NeuroMetrix akcijų simbolis yra NURO.

Per paskutinius 12 mėnesių NeuroMetrix išmokėjo dividendą, kurios dydis siekė 1 728,00 USD . Tai atitinka maždaug 60 209,06 % dividendų grąžą. Artimiausiems 12 mėnesiams NeuroMetrix tikėtina išmokės dividendus, kurie sudarys 0 USD.

NeuroMetrix šiuo metu yra 60 209,06 % dydžio dividendų grąža.

NeuroMetrix moka dividendus kas ketvirtį. Jie išmokami mėnesiais.

NeuroMetrix per paskutiniuosius 0 metus kiekvienais metais mokėjo dividendus.

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0 USD. Tai atitinka 0 % dividendų grąžos procentą.

NeuroMetrix priskiriamas sektoriui "Sveikata".

Norėdamas gauti paskutinį NeuroMetrix dividendą nuo 2007-04-13, kurio dydis yra 0,15 USD, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2007-03-28.

Paskutinės dividendų išmokėjimas įvyko 2007-04-13.

2023 metais NeuroMetrix išmokėjo 0 USD dividendų.

NeuroMetrix dividendai yra mokami USD.